INDIA The Future Hub of Drug Discovery Services?*



Case Code : CLINDM 006
Publication date : 2006
Subject : Industrial Marketing
Industry : Pharma and Biotech
Teaching Note : Available
Length : 07 Pages
Price : Rs. 100

To download this case click on the button below, and select the case from the list of available cases:

Industrial Marketing
Short Case Studies

Marketing Case Studies**
Case Studies Collection
ICMR Courseware
View Detailed Pricing Info

Key words:

Biocon, Syngene, Ranbaxy, Cipla, Dr.Reddy's, Drug discovery services, Pharma value chain, External service providers, Clinical research organizations, Integrated service providers, Blockbuster drug, Intellectual Property Rights, Patents, Multiyear agreement, Lead optimization project, Market potential, Middlemen, Lipitor, Atorvastatin, Chemists, Pfizer, biomedical research.


* This caselet is intended for use only in class discussions.
** More comprehensive case studies are priced at Rs.200 to Rs.700 (US $5 to US $16) per copy.


ICMR India ICMR India ICMR India ICMR India RSS Feed

The caselet examines the various problems faced by the pharma majors in the developed countries, especially in terms of high drug discovery and development costs. This led to pharma majors outsourcing certain tasks in the drug discovery process to Asian countries, especially India. The latter portion of the case looks into the Indian perspective and focuses on the advantages and disadvantages faced by the Indian drug discovery services industry.


   The importance of drug discovery services
   Types of drug discovery services and their respective roles
   Reducing cost of operations in developed nations
   The importance of outsourcing some tasks of the pharma value chain
   The benefits reaped and the problems faced by the Indian drug discovery service companies


Drug discovery services are one of the fastest growing segments in industrial services around the world. India and other Asian countries have become major markets for many global pharmaceutical (pharma) companies to outsource some parts of the pharma value chain.

According to the Confederation of Indian Industry (CII) estimates, the global market for outsourced R&D services (which included drug discovery services and clinical research) was around US$7 billion in 2005 and was expected to grow at around 30% per annum for the next five years.

Questions for Discussion:

1. Perform a SWOT analysis of the drug discovery services industry in view of the recent developments in this sector.

2. Do you think India will emerge as an undisputed leader in this domain in the coming years? Give reasons for your answer.